MarketScreener Homepage > Equities > Nasdaq > PPD, Inc. PPD

Report

Real-time Estimate Cboe BZX - 01/21 11:15:52 am
35.53	USD		-0.92%

01/14

PPD, INC. : Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)

01/11

PPD, INC. : Regulation FD Disclosure (form 8-K)

01/11

EQS-NEWS : Relief, NeuroRx and Quantum Leap announce the inclusion of ZYESAMI(TM) (RLF-100(TM): aviptadil) in the I-SPY COVID-19 Trial

Summary

Strengths

Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The stock is in a well-established, long-term rising trend above the technical support level at 23.2 USD

Weaknesses

The share is close to its long-term resistance in weekly data. Therefore, the potential should be limited. However, a further bullish movement when crossing this resistance will be a positive signal.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
With an expected P/E ratio at 89.27 and 35.38 respectively for both the current and next fiscal years, the company operates with high earnings multiples.

Sector Biotechnology & Medical Research - NEC



MODERNA, INC.	19.79%	49 468
LONZA GROUP AG	1.97%	48 472
CELLTRION, INC.	-13.37%	38 667
IQVIA HOLDINGS INC.	6.35%	36 230
SEAGEN INC.	8.94%	34 149
HANGZHOU TIGERMED CONSULTIN..	7.64%	21 275
INCYTE CORPORATION	8.02%	20 577
ALNYLAM PHARMACEUTICALS, IN..	31.55%	19 566
PHARMARON BEIJING CO., LTD.	16.82%	15 255
CRISPR THERAPEUTICS AG	29.51%	14 657
CHARLES RIVER LABORATORIES ..	11.62%	13 873
BIO-TECHNE CORPORATION	12.32%	13 582
QIAGEN N.V.	1.87%	12 316
ICON PUBLIC LIMITED COMPANY	13.32%	11 353
IONIS PHARMACEUTICALS, INC.	10.61%	8 533

Financials (USD)

Upcoming event on PPD, INC.

03/10/21

Fundamental ratings

Technical ratings